Product nameAnti-Vaccinia Virus antibody
See all Vaccinia Virus primary antibodies
DescriptionRabbit polyclonal to Vaccinia Virus
SpecificityThis antibody reacts with purified Virions. It does not react with uninfected cells.
Tested applicationsSuitable for: ELISA, WB, IHC-P, IHC-Fr, ICC/IFmore details
Species reactivityReacts with: Vaccinia virus
Native virus, Lister strain.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferPreservative: 0.1% Sodium Azide
Constituents: PBS, pH 7.2
Concentration information loading...
Purification notesThis antibody is greater than 95% pure.
Our Abpromise guarantee covers the use of ab35219 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ELISA||1/500 - 1/2000.|
|WB||Use at an assay dependent concentration. Predicted molecular weight: 14 kDa. PubMed: 25093734|
|IHC-P||Use at an assay dependent concentration. PubMed: 25093734|
|IHC-Fr||Use at an assay dependent concentration.|
|ICC/IF||Use at an assay dependent concentration. PubMed: 22615950|
RelevanceVaccinia virus is an Orthopoxvirus, containing double stranded DNA. Fusion protein plays an important role in the entry of enveloped virus into cells. As vaccinia virus has a wide host range, it is conceivable that certain cellular components that are ubiquitously expressed on the cell mediate virus infection. The study of the entry process, attachment, fusion and the proteins and receptors involved is complex. During vaccinia virus infection, the fusion process is attributed to the action of the 14KDa protein (A27L). The N terminus of this protein recognises heparan sulfate on the cell surface. It interacts with the negative charges of sulfates of glycosaminoglycans (GAGs). Therefore, antibodies that recognize this 14KDa protein are able to neutralize vaccinia virus infection and enable identification other viral and cellular proteins which participate in the vaccinia virus entry process.
- A27L antibody
- Orthopoxvirus antibody
All lanes :
Lane 1 : DT09/06cells infected with GLV-5b451 Vaccina Virus (24 hours post infection)
Lane 2 : DT09/06cells infected with GLV-5b451 Vaccina Virus (48 hours post infection)
Lane 3 : DT09/06cells infected with GLV-5b451 Vaccina Virus (72 hours post infection)
Lane 4 : DT09/06cells infected with GLV-5b451 Vaccina Virus (96 hours post infection)
Lane 5 : DT09/06 cells infected with LIVP 6.1.1 Vaccina Virus (24 hours post infection)
Lane 6 : DT09/06 cells infected with LIVP 6.1.1 Vaccina Virus (48 hours post infection)
Lane 7 : DT09/06 cells infected with LIVP 6.1.1 Vaccina Virus (72 hours post infection)
Lane 8 : DT09/06 cells infected with LIVP 6.1.1 Vaccina Virus (96 hours post infection)
Lane 9 : Mock infected DT09/06 cells (24 hours)
Lane 10 : Mock infected DT09/06 cells (48 hours)
Lane 11 : Mock infected DT09/06 cells (72 hours)
Lane 12 : Mock infected DT09/06 cells (96 hours)
Developed using the ECL technique.
Predicted band size: 14 kDa
Data from: PLoS One (2014) 9, e104337.
Adelfinger, M., Gentschev, I., de Guilbert, J.G., Weibel, S., Langnein-Laugwitz, J., Hartl, B., Escobar, H.M., Nolte, I., Chen, N.G., Aguilar, R.J., Yu, Y.A., Zhang, Q., Frentzen, A. and Szalay, A.A.
Formalin/PFA-fixed paraffin-embedded mouse cornea stained for Vaccinia Virus with ab35219 at 1/40 dilution in immunohistochemical analysis.
Heat mediated antigen retrieval was performed in Tris buffer at pH 9.0.
WR strain of Vaccina Virus.
This product has been referenced in:
- O'Leary MP et al. Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose. J Transl Med 16:110 (2018). Read more (PubMed: 29699566) »
- O'Leary MP et al. A Novel Oncolytic Chimeric Orthopoxvirus Encoding Luciferase Enables Real-Time View of Colorectal Cancer Cell Infection. Mol Ther Oncolytics 9:13-21 (2018). Read more (PubMed: 29988502) »